Dr. Dan Zabrowski is a Venture Partner at Decheng Capital and has been with the firm since July 2016. He is currently serving on the boards of AccuraGen, Apexigen, Ariagen, BeyondSpring (NASDAQ: BYSI) and Encodia. He previously served on the boards of Omniome (acquired by Pacific Biosciences) and ReadCoor (acquired by 10X Genomics).
Prior to joining Decheng, Dr. Zabrowski worked over 20 years for Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. During his tenure in Business Development and Diagnostics, Dr. Zabrowski and his teams delivered 300+ acquisition and partnership deals. In addition, he was Board member of Chugai Pharmaceuticals. Prior to joining Roche, Dr. Zabrowski worked at Syntex, Fujisawa (now Astellas) and G.D. Searle in their pharmaceutical R&D organizations and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois — Chicago. Dr. Zabrowski received his PhD in Organic Chemistry from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University.